Common and rare variants in complement genes as biomarkers of COVID-19 infection and severity. A lesson to learn for emerging pathogens - Takeaways - MDSpire

Common and rare variants in complement genes as biomarkers of COVID-19 infection and severity. A lesson to learn for emerging pathogens

  • By

  • María Eugenia De La Morena-Barrio

  • Ana Van Den Rym

  • Olga Escorial Sanz

  • Fernando Corvillo

  • Rosario García-Sánchez

  • Laura González-Sánchez

  • Adrián Muñoz-Barrera

  • Rafaela González-Montelongo

  • José Miguel Lorenzo-Salazar

  • Carlos Flores

  • Ana de Andrés-Martín

  • Carlos Rodríguez-Gallego

  • Luis Allende

  • Laia Alsina

  • Silvia Sánchez-Ramón

  • Eduardo López-Collazo

  • Margarita López-Trascasa

  • Pilar Sánchez-Corral

  • Rebeca Pérez de Diego

  • Javier Corral de la Calle

  • Alberto López-Lera

  • June 11, 2026

  • 0 min

Share

  • 1

    The study analyzed genetic variants in complement pathway genes among 154 Spanish adults hospitalized with severe COVID-19.

  • 2

    Common polymorphisms CFHR4 rs7417769 and CFH rs1061170 were linked to protection against acute respiratory distress syndrome (ARDS).

  • 3

    Variants C3 rs2230199 and MASP2 rs7255087 correlated with C3 levels, indicating their role in COVID-19 severity.

  • 4

    Over-representation of C1R rs117402032 and C8A rs143523574 polymorphisms suggests defective complement activation increases SARS-CoV-2 infection rates.

  • 5

    The findings highlight potential genetic biomarkers for predicting COVID-19 severity and preparedness for future infectious threats.

Original Source(s)

Common and rare variants in complement genes as biomarkers of COVID-19 infection and severity. A lesson to learn for emerging pathogens

  • by María Eugenia De La Morena-Barrio, Ana Van Den Rym, Olga Escorial Sanz, Fernando Corvillo, Rosario García-Sánchez, Laura González-Sánchez, Adrián Muñoz-Barrera, Rafaela González-Montelongo, José Miguel Lorenzo-Salazar, Carlos Flores, Ana de Andrés-Martín, Carlos Rodríguez-Gallego, Luis Allende, Laia Alsina, Silvia Sánchez-Ramón, Eduardo López-Collazo, Margarita López-Trascasa, Pilar Sánchez-Corral, Rebeca Pérez de Diego, Javier Corral de la Calle, Alberto López-Lera

  • June 11, 2026

Related Content

The stand-alone Ayurveda treatment for the management of COVID-associated mucormycosis (CAM): a case report

Optimizing drug combinations to resurrect the potency of failed antibody therapy against emerging COVID-19 variants using IDentif.AI

Decision Aids for Vaccination in an Era of Medical Freedom